Patent 12403095
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Active provider: Google · gemini-2.5-pro
No PTAB proceedings on file. This patent has not been challenged through Inter Partes Review, Post-Grant Review, or Covered Business Method review at the USPTO. The absence is itself a signal — well-asserted patents eventually attract IPRs.
Cases on file (2)
Group view →Specific litigation cases in our database that name US patent 12403095. The free-form analysis below may also discuss cases beyond this list.
- Veloxis Pharmaceuticals AS v. Zydus Cadila et al.filed Apr 23, 20261:26-cv-00467Delaware District CourtOpen
Defendants: Zydus Cadila and Zydus Lifesciences Ltd
Other patents asserted: 11419823, 10864199, 8685998, 8664239, 11123331, 10166190, 11110081, 12083103, 9549918
The accused products are the 0.75 mg, 1 mg, and 4 mg extended-release tacrolimus tablets sold under the brand name ENVARSUS XR.
- Veloxis Pharmaceuticals, Inc. v. Glenmark Pharmaceuticals Inc., USAfiled Mar 20, 20261:26-cv-00305U.S. District Court for the District of Delawareopen
Defendants: Glenmark Pharmaceuticals Inc., USA
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Litigation Status of U.S. Patent 12,403,095
As of May 1, 2026, U.S. Patent 12,403,095 is involved in at least two known litigations, both of which are Abbreviated New Drug Application (ANDA) cases filed in the U.S. District Court for the District of Delaware. These cases typically arise when a generic drug manufacturer seeks FDA approval to market a generic version of a branded drug before the expiration of patents covering that drug.
Details of the cases are as follows:
Case 1
- Plaintiff(s): Veloxis Pharmaceuticals, Inc.
- Defendant(s): Glenmark Pharmaceuticals Inc., USA
- Jurisdiction: U.S. District Court for the District of Delaware
- Case Number: 1:26-cv-00305
- Filing Date: March 20, 2026
- Outcome or Current Status: The case is currently open.
Case 2
- Plaintiff(s): Veloxis Pharmaceuticals, Inc.
- Defendant(s): Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Ltd.
- Jurisdiction: U.S. District Court for the District of Delaware
- Case Number: 1:26-cv-00467
- Filing Date: April 23, 2026
- Outcome or Current Status: The case is currently open. In this case, the '095 patent is listed among several others with an anticipated expiration date of May 30, 2028, and a thirty-month stay deadline of September 12, 2028.
Generated 5/1/2026, 10:54:56 PM